By Meghan Hosely, Marketing Content Writer
The global pandemic caused by the coronavirus (SARS-CoV-2) and the disease it causes (COVID-19) have brought genetic research to the forefront. Currently available genetic engineering techniques and the single SARS-CoV-2 genome sequence provide a wealth of opportunities for research and development of new vaccines. In fact, the most prominent vaccine candidates contain engineered genetic material.
Gene therapy research continues its rapid expansion in the clinical setting, with 2019 marking an all-time high number of investigational new drug (IND) applications for gene therapy products. Areas like oncology, rare diseases, and infectious diseases have particularly benefited from this boom. The field has overcome many obstacles to reach its current state where the Food and Drug Administration (FDA) has begun issuing approvals. While great strides have been made in genetic research, to continue, some remaining obstacles need to be addressed.
In an effort to begin conversations about these obstacles, Advarra presents its first virtual symposium, Gene Therapy Research in the Age of COVID-19: Study Startup Success for Infectious Disease, Oncology, and Rare Disease Research. The symposium will take place on Wednesday, June 3, at 1:00 pm EDT/10:00 am PDT, and features a virtual panel discussion on emerging issues in gene therapy research.